Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Generic 180-Day Exclusivities Might Be Imperiled By ANDA Stability Guidance

Executive Summary

Industry experts predict generic company pushback on some aspects of Q&A draft guidance and worry about unintended consequences, including impact on drug master files.

You may also be interested in...

ANDA Stability Requirements To Be Broadly Grandfathered, FDA Says

In a win-win for agency and industry, generic applications submitted before deadline for new stability requirements still will be judged by old standards, even if the ANDAs are amended or resubmitted.

ANDAs To Include Six Months Of Stability Test Data Under FDA Draft Guidance

The agency advises sponsors to follow the stability testing recommendations in the International Conference on Harmonization guidances; three companies submit comments seeking clarification from FDA.

Medicare Payment Cuts For Vaccines: MedPac Suggests Moving To New WAC-Reimbursement Formula

Proposal, which could be formally endorsed by MedPac this spring, would lower the payment rates for vaccines while simultaneously moving all preventative vaccine coverage to Medicare Part B. Commission signals further cuts to payment rate, through an average sales priced-based methodology that might eventually be recommended.


Related Companies




Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts